Results 291 to 300 of about 4,732,777 (361)

Evolution of neoadjuvant therapy for breast cancer regimens over 12 years and pathologic response rates according to tumor subtypes and clinical stage: A single-center retrospective study

Zhedong Li, Yongsheng Wang
openalex   +1 more source

Prognostic value of pan-immune-inflammation in breast cancer patients with lymph node metastasis and neoadjuvant therapy. [PDF]

Medicine (Baltimore)
Wang Z, Wu X, Yang L, Guo Y, Zeng X, Yan X, Chen J.   +6 more
europepmc   +1 more source

Artificial Intelligence-Based Pathology to Assist Prediction of Neoadjuvant Therapy Responses for Breast Cancer. [PDF]

Cancer Med
Ji J, Duan F, Liao Q, Wang H, Liu S, Liu Y, Huang Z.   +6 more
europepmc   +1 more source

Commentary: Revisiting the Radiation Dose in Neoadjuvant Therapy for Esophageal Cancer: Insights from a High-Dose Strategy. [PDF]

J Chest Surg
Na KJ.
europepmc   +1 more source

Total neoadjuvant therapy for locally advanced rectal cancer. [PDF]

Cochrane Database Syst Rev
Mueller S, Kao YS, Kastner C, Chen PH, Hendricks A, Lee GY, Koehler F, Jhou HJ, Germer CT, Kang EY, Janka H, Ho CL, Lee CH, Wiegering A.   +13 more
europepmc   +1 more source

Effect of neoadjuvant therapy on survival outcomes in patients with melanoma: a systematic review and meta-analysis. [PDF]

EClinicalMedicine
Yuan F, Jing M, Chen X, Zhang X.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Neoadjuvant therapy for pancreatic cancer

Nature Reviews Clinical Oncology, 2023
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with surgical resection of the primary tumour and systemic chemotherapy, which provides considerably longer overall survival (OS) durations than either modality alone. Regardless, most patients will have disease relapse owing to micrometastatic disease.
Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, Philip A. Philip, Theodore S. Hong, Thilo Hackert, Markus W. Büchler, John Neoptolemos   +7 more
openaire   +3 more sources

Breast MRI for Evaluation of Response to Neoadjuvant Therapy.

Radiographics, 2021
Neoadjuvant therapy is increasingly being used to treat early-stage triple-negative and human epidermal growth factor 2-overexpressing breast cancers, as well as locally advanced and inflammatory breast cancers. The rationales for neoadjuvant therapy are
B. Reig, Alana A. Lewin, Linda Du, L. Heacock, H. Toth, S. Heller, Yiming Gao, L. Moy   +7 more
semanticscholar   +1 more source

Neoadjuvant Therapy for Melanoma

Surgical Oncology Clinics of North America, 2020
With the universal adoption of immune checkpoint blockade and agents targeting BRAF-mutated melanomas in the metastatic setting, numerous clinical trials have evaluated these agents in the neoadjuvant setting. These smaller trials have shown promising results with high pathologic response rates and acceptable safety.
Michael C, Lowe, Ragini R, Kudchadkar
openaire   +2 more sources